GPRC5D and Miyoshi myopathy: Pre-clinical studies suggest that CAR NK efficacy against MM may be further enhanced by targeting multiple neoplastic receptors such as GPRC5D/CD38 or GPRC5D/BCMA or focusing on other targets such as CD70 [234,235].